The value of NETest 2.0 in stratifying patients with suspected NEN for formal diagnostic evaluation – Real-world data

#4409

Introduction: An unmet need in NEN diagnosis is better risk stratification for individuals with suspected disease (based on symptoms or imaging), enabling efficient identification of those needing further evaluation and tissue diagnosis, thus speeding the process and reducing costs. NETest 2.0, a biomarker based on a 51-gene mRNA panel, was developed for diagnosing neuroendocrine neoplasia (NEN).

Aim(s): To assess NETest 2.0's value for stratifying an "at-risk" Swiss NEN cohort and compare its clinical utility to Chromogranin A (CgA).

Materials and methods: The study included 62 consecutive subjects with symptoms (n=23) or imaging findings (n=39, mainly FDG-PET) suspicious for NEN. Blood samples for CgA and NETest were collected from all subjects, deidentified, and measured blinded. CgA positivity was set at ≥102 µg/L, NETest positivity at ≥50. Fisher’s exact test and diagnostic metrics were used. Formal NEN diagnosis confirmed by histology.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, at-risk population, NEN,